Dose-Dense AC Followed by Taxol With Herceptin Is Feasible

A mature 70-patient report by Chau T. Dang, MD, et al, on cardiac safetyof dose-dense AC (doxorubicin and cyclophosphamide, 60/600 mg/m2 X4) followed by Taxol with Herceptinfor 52 weeks in HER2-positivepatients, has concluded that theregimen is feasible; 3 of 70 patients (4%) had cessation oftrastuzumab because of asymptomaticLVEF decline, about 6 monthsinto the treatment period.

A mature 70-patient report by ChauT. Dang, MD, et al, on cardiac safetyof dose-dense AC (doxorubicin andcyclophosphamide, 60/600 mg/m2 ×4) followed by Taxol with Herceptinfor 52 weeks in HER2-positivepatients, has concluded that theregimen is feasible (abstract 2101); 3of 70 patients (4%) had cessation oftrastuzumab because of asymptomaticLVEF decline, about 6 monthsinto the treatment period. No significantLVEF declines were observedafter dose-dense AC, as assessed bymonth 2 MUGA. One patient hadCHF at month 4 of treatment (baselineEF > 75% dropped to 45%). Investigatorsreported she is clinically wellon diuretic, ACE-inhibitor, and beta-blocker.